Portal de Periódicos da CAPES

Aerosol Administration of Fenoterol Hydrobromide (Th 1165a) in Subjects with Reversible Obstructive Airway Disease

1977; Elsevier BV; Volume: 72; Issue: 6 Linguagem: Inglês

10.1378/chest.72.6.731

1931-3543

Bernard E. Pennock, Robert M. Rogers, Billy R. Ryan, Larry Ayers,

Asthma and respiratory diseases

Bronchodilator and side effects of fenoterol hydrobromide (Th1165a; hydroxyphenylorciprenaline; Berotec) and isoproterenol given by inhalation were compared in a double-blind crossover study involving 20 volunteer subjects with reversible obstructive disease of the airways. Subjects inhaled medications from aerosol canisters containing fenoterol hydrobromide (0.1 mg, 0.2 mg, or 0.4 mg) or isoproterenol (0.15 mg) or an inert placebo propellant in a random sequence of five testing days. All active drugs substantially increased the forced expiratory volume in one second, the mean forced expiratory flow during the middle half of the forced vital capacity, and the specific conductance. The onset of bronchodilation after both fenoterol and isoproterenol was rapid, but the effect from fenoterol lasted much longer, up to eight hours. None of the medications caused significant tachycardia or hypertension. After inhalation of 0.1 mg of fenoterol hydrobromide, none of the subjects reported nervousness, headache, tremor, or nausea, in contrast with results reported for isoproterenol, higher aerosol doses of fenoterol, or oral administration of fenoterol. No additional therapeutic benefit was found in the administration of higher doses of fenoterol. Bronchodilator and side effects of fenoterol hydrobromide (Th1165a; hydroxyphenylorciprenaline; Berotec) and isoproterenol given by inhalation were compared in a double-blind crossover study involving 20 volunteer subjects with reversible obstructive disease of the airways. Subjects inhaled medications from aerosol canisters containing fenoterol hydrobromide (0.1 mg, 0.2 mg, or 0.4 mg) or isoproterenol (0.15 mg) or an inert placebo propellant in a random sequence of five testing days. All active drugs substantially increased the forced expiratory volume in one second, the mean forced expiratory flow during the middle half of the forced vital capacity, and the specific conductance. The onset of bronchodilation after both fenoterol and isoproterenol was rapid, but the effect from fenoterol lasted much longer, up to eight hours. None of the medications caused significant tachycardia or hypertension. After inhalation of 0.1 mg of fenoterol hydrobromide, none of the subjects reported nervousness, headache, tremor, or nausea, in contrast with results reported for isoproterenol, higher aerosol doses of fenoterol, or oral administration of fenoterol. No additional therapeutic benefit was found in the administration of higher doses of fenoterol. New Drugs for Asthma: A Scientific Basis for TherapyCHESTVol. 72Issue 6PreviewDrugs effective in the treatment of asthma have been discovered empirically over a span of three generations. Of the seven drugs listed in an 1889 formulary for asthma, none is in use today, though derivatives of one with anticholinergic activity may still prove useful in treating asthma. The introduction of injectable epinephrine in 1903 marked a significant advance in the treatment of acute asthma. Ephedrine, the active ingredient of the herb ma huang used by the Chinese for 5,000 years to treat asthma, and by the Japanese in pure form since 1885, was introduced into Western medicine in 1925 as the first orally effective bronchodilator. Full-Text PDF